These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31178335)

  • 21. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
    Abdo WF; De Jong D; Hendriks JC; Horstink MW; Kremer BP; Bloem BR; Verbeek MM
    Mov Disord; 2004 May; 19(5):571-9. PubMed ID: 15133823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural history of multiple system atrophy in the USA: a prospective cohort study.
    Low PA; Reich SG; Jankovic J; Shults CW; Stern MB; Novak P; Tanner CM; Gilman S; Marshall FJ; Wooten F; Racette B; Chelimsky T; Singer W; Sletten DM; Sandroni P; Mandrekar J
    Lancet Neurol; 2015 Jul; 14(7):710-9. PubMed ID: 26025783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cross-sectional study on drug use in multiple system atrophy.
    Rey MV; Perez-Lloret S; Pavy-Le Traon A; Meissner WG; Tison F; Rascol O
    CNS Drugs; 2014 May; 28(5):483-90. PubMed ID: 24683045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines in the cerebrospinal fluids of patients with chronic fatigue syndrome/myalgic encephalomyelitis.
    Peterson D; Brenu EW; Gottschalk G; Ramos S; Nguyen T; Staines D; Marshall-Gradisnik S
    Mediators Inflamm; 2015; 2015():929720. PubMed ID: 25834308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative.
    Laurens B; Constantinescu R; Freeman R; Gerhard A; Jellinger K; Jeromin A; Krismer F; Mollenhauer B; Schlossmacher MG; Shaw LM; Verbeek MM; Wenning GK; Winge K; Zhang J; Meissner WG
    Neurobiol Dis; 2015 Aug; 80():29-41. PubMed ID: 25982836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis.
    Xie D; Feng L; Huang H; Zhao Q; Ning P; Shen Q; Lu H; Xu F; Xu Y
    Behav Neurol; 2021; 2021():5559383. PubMed ID: 34158872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).
    Geser F; Wenning GK; Seppi K; Stampfer-Kountchev M; Scherfler C; Sawires M; Frick C; Ndayisaba JP; Ulmer H; Pellecchia MT; Barone P; Kim HT; Hooker J; Quinn NP; Cardozo A; Tolosa E; Abele M; Klockgether T; Østergaard K; Dupont E; Schimke N; Eggert KM; Oertel W; Djaldetti R; Poewe W;
    Mov Disord; 2006 Feb; 21(2):179-86. PubMed ID: 16161136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor-β1 in the cerebrospinal fluid of patients with distinct neurodegenerative diseases.
    Masuda T; Itoh J; Koide T; Tomidokoro Y; Takei Y; Ishii K; Tamaoka A
    J Clin Neurosci; 2017 Jan; 35():47-49. PubMed ID: 27756506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
    Goldstein DS; Holmes C; Sullivan P; Jinsmaa Y; Kopin IJ; Sharabi Y
    Parkinsonism Relat Disord; 2016 Oct; 31():79-86. PubMed ID: 27474472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.
    Köllensperger M; Geser F; Ndayisaba JP; Boesch S; Seppi K; Ostergaard K; Dupont E; Cardozo A; Tolosa E; Abele M; Klockgether T; Yekhlef F; Tison F; Daniels C; Deuschl G; Coelho M; Sampaio C; Bozi M; Quinn N; Schrag A; Mathias CJ; Fowler C; Nilsson CF; Widner H; Schimke N; Oertel W; Del Sorbo F; Albanese A; Pellecchia MT; Barone P; Djaldetti R; Colosimo C; Meco G; Gonzalez-Mandly A; Berciano J; Gurevich T; Giladi N; Galitzky M; Rascol O; Kamm C; Gasser T; Siebert U; Poewe W; Wenning GK;
    Mov Disord; 2010 Nov; 25(15):2604-12. PubMed ID: 20922810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frontal lobe function, behavioral changes and quality of life in patients with multiple system atrophy.
    Zhang L; Cao B; Zou Y; Wei QQ; Ou R; Zhao B; Yang J; Wu Y; Shang H
    Restor Neurol Neurosci; 2019; 37(1):11-19. PubMed ID: 30741706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraventricular cerebrospinal fluid temperature analysis using MR diffusion-weighted imaging thermometry in Parkinson's disease patients, multiple system atrophy patients, and healthy subjects.
    Sumida K; Sato N; Ota M; Sakai K; Nippashi Y; Sone D; Yokoyama K; Ito K; Maikusa N; Imabayashi E; Matsuda H; Yamada K; Murata M; Kunimatsu A; Ohtomo K
    Brain Behav; 2015 Jun; 5(6):e00340. PubMed ID: 26085965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The European Multiple System Atrophy-Study Group (EMSA-SG).
    Geser F; Seppi K; Stampfer-Kountchev M; Köllensperger M; Diem A; Ndayisaba JP; Ostergaard K; Dupont E; Cardozo A; Tolosa E; Abele M; Dodel R; Klockgether T; Ghorayeb I; Yekhlef F; Tison F; Daniels C; Kopper F; Deuschl G; Coelho M; Ferreira J; Rosa MM; Sampaio C; Bozi M; Schrag A; Hooker J; Kim H; Scaravilli T; Mathias CJ; Fowler C; Wood N; Quinn N; Widner H; Nilsson CF; Lindvall O; Schimke N; Eggert KM; Oertel W; del Sorbo F; Carella F; Albanese A; Pellecchia MT; Barone P; Djaldetti R; Meco G; Colosimo C; Gonzalez-Mandly A; Berciano J; Gurevich T; Giladi N; Galitzky M; Ory F; Rascol O; Kamm C; Buerk K; Maass S; Gasser T; Poewe W; Wenning GK;
    J Neural Transm (Vienna); 2005 Dec; 112(12):1677-86. PubMed ID: 16049636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered structural connectivity of the motor subnetwork in multiple system atrophy with cerebellar features.
    Shah A; Prasad S; Rastogi B; Dash S; Saini J; Pal PK; Ingalhalikar M
    Eur Radiol; 2019 Jun; 29(6):2783-2791. PubMed ID: 30552481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.
    Abdo WF; Bloem BR; Van Geel WJ; Esselink RA; Verbeek MM
    Neurobiol Aging; 2007 May; 28(5):742-7. PubMed ID: 16678934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study.
    Starhof C; Hejl AM; Korbo L; Winge K; Friis S
    Neuroepidemiology; 2020; 54(1):58-63. PubMed ID: 31661696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.